Characterization of immune responses induced by inactivated, live attenuated and DNA vaccines against Japanese encephalitis virus in mice

Characterization of immune responses induced by inactivated, live attenuated and DNA vaccines against Japanese encephalitis virus in mice
复制标题

DOI：
10.1016/j.vaccine.2013.06.099
复制
发表时间：
2013-08-28
期刊：
VACCINE
影响因子：
5.5
通讯作者：
An, Jing
An, Jing
中科院分区：
医学3区
文献类型：
--
作者：
Li, Jieqiong;Chen, Hui;An, Jing

文献摘要

被引文献

相似文献

疫苗接种是保护个人免受日本脑炎病毒（JEV）感染的最有效对策。目前我国使用的乙脑疫苗有两种：Vero细胞灭活疫苗和减毒活疫苗。在这项研究中，我们表征了灭活疫苗、减毒活疫苗和表达 JEV prM-E 蛋白的 DNA 候选疫苗 pCAG-JME 在小鼠中诱导的免疫反应和保护功效。我们发现减毒活疫苗可提供 100% 的保护，并导致产生高水平的特异性抗 JEV 抗体和细胞因子。 pCAG-JME 疫苗与减毒活疫苗一样诱导保护性免疫。出乎意料的是，用灭活疫苗免疫仅诱导有限的免疫反应和部分保护，这可能是由于在这些小鼠中观察到的树突状细胞活性降低和CD4+CD25+Foxp3+调节性T细胞扩增所致。总而言之，我们的结果表明，减毒活疫苗比灭活疫苗更能有效地提供针对 JEV 感染的保护，并且 pCAG-JME 将成为潜在的 JEV 疫苗候选者。 (C) 2013 Elsevier Ltd. 保留所有权利。
Vaccination is the most effective countermeasure for protecting individuals from Japanese encephalitis virus (JEV) infection. There are two types of JEV vaccines currently used in China: the Vero cell-derived inactivated vaccine and the live attenuated vaccine. In this study, we characterized the immune response and protective efficacy induced in mice by the inactivated vaccine, live attenuated vaccine and the DNA vaccine candidate pCAG-JME, which expresses JEV prM-E proteins. We found that the live attenuated vaccine conferred 100% protection and resulted in the generation of high levels of specific anti-JEV antibodies and cytokines. The pCAG-JME vaccine induced protective immunity as well as the live attenuated vaccine. Unexpectedly, immunization with the inactivated vaccine only induced a limited immune response and partial protection, which may be due to the decreased activity of dendritic cells and the expansion of CD4+CD25+Foxp3+ regulatory T cells observed in these mice. Altogether, our results suggest that the live attenuated vaccine is more effective in providing protection against JEV infection than the inactivated vaccine and that pCAG-JME will be a potential JEV vaccine candidate. (C) 2013 Elsevier Ltd. All rights reserved.